Our cells have noise-cancellation headphones. Now our website does a better job explaining why. 🎧
A few fun updates to @KiraGenBio, including a refreshed look at KiraLOGIC and how we choose which gene-edit combinations to build and test next.
kiragenbio.com
Ex vivo CAR-T can cure solid tumors. The cells just need the right tools to survive & do their job.
That is exactly the thesis behind @KiraGenBio: engineer better cells, learn from patients, & build the systems to turn remarkable responses into scalable cures.
CAR-T therapies engineer patients’ immune cells to kill cancer and they have achieved remarkable results in blood cancers that resist other treatments.
Solid tumors (e.g. liver, breast cancer) have proved much harder -- until now.
This new report of one patient in a Phase I trial offers a very promising example of progress: a three-year-old with chemotherapy-resistant metastatic liver cancer achieved complete remission lasting at least a year -- a truly breakthrough result considering the severity of this cancer.
The history of how this results came about shows how CAR-T progress depends on repeated cycles of engineering, testing in patients and learning from the results. Most of this iterative learning happens in Phase I trials like the current one, which shows how important such studies are for driving medical progress forward.
One additional difficulty for solid tumors is that they suppress immune activity, which in turn makes it difficult for CAR-T cells to sustain an attack. So to extend CAR-T’s success in blood cancers to solid tumors, researchers had to help the engineered cells survive in this more hostile territory.
In 2020, the team’s earlier clinical work across 4 Phase I trials tested CAR-T cells targeting glypican-3, a protein on certain solid tumors. In 12 patients, these cells produced no objective tumor responses. Another 12 received cells engineered to also produce IL-15, a naturally occurring immune signaling protein that helps T cells survive and multiply. Although 4 patients responded, none achieved complete remission.
But the responses were promising and revealed that there was value in giving CAR-Ts their own survival signals. So the researchers doubled down on this lesson.
In this new Phase I study, built on the learnings from the previous one, researchers engineered the expression of two different cytokines – IL-15 and IL-21. They also added an emergency off switch that allows doctors to destroy the engineered cells if necessary to reduce toxicity.
Remarkably, a first infusion shrank the cancer of the 3 year old patient and a after a second, the remaining tumor disappeared. A year later the patient remained disease-free.
There is an obvious caveat here: one patient cannot definitively establish how reliably the treatment works. But the results are striking enough to offer real hope that this would work in at least a subset of patients.
I believe this development beautifully illustrates why Phase I trials matter: they let researchers observe how engineered cells behave inside patients and carry those lessons into further development. I am committed to making these studies easier to run in order to accelerate this cycle of iterative learning.
@Doug_Cartwright is sharing his journey in Penn’s GBM CAR-T trial. Give him a follow.
A powerful reminder of why this work matters so much to us at @KiraGenBio.
Huge respect for Doug, @StephenBagleyMD, @DrORourke2 & the entire Penn team.
Rooting for you (& those CAR-T cells!)
Our new @KiraGenBio website is live!
A lead program in GBM. A system for what comes next.
One focus: programmable durability for solid-tumor cell therapy.
kiragenbio.com
This is why we built @KiraGenBio.
Base editing made CAR-T possible for patients like Alyssa, CURED of T-cell leukemia after every other option failed. We built the U.S. version at @BeamTx.
Help us make more stories like Alyssa’s for patients with GBM and other solid tumors!
After leukemia treatments failed, Alyssa Tapley, at age 13, was told she would die. Then, doctors tried an experimental gene-edited therapy. She became the first human to try the treatment made possible by U.S. federal funding. Now 16, she’s cancer-free and planning her future. cbsn.ws/4ou0OMt
Our new website is live 🚀
KiraGen Bio is advancing multiplex-edited, off-the-shelf cell therapies designed to block tumor suppression signals and bring durable treatments to solid tumors.
Explore more → kiragenbio.com
Meet the newest member of Team @KiraGenBio — our CAR-T cell mascot 🎧
Outfitted with AI-powered, noise-canceling headphones (our multiplex gene edits), it’s built to block out the solid tumor suppressive “noise” & keep fighting on!
Designed to cure. Built to endure.
Our TME-Guards are like noise-cancelling headphones for CAR-T cells — silencing the suppressive signals of the tumor microenvironment so they can do their job.
We are honored to be part of the inaugural AI BioHub from @c10labs & @LabCentral—bringing AI and biology together to accelerate the future of drug development.
Excited to share that @KiraGenBio has been selected to join the inaugural AI BioHub from @c10labs & @LabCentral!
We’re building multiplex-edited CAR-T therapies guided by AI—and thrilled to be part of a cohort pushing the future of #TechBio forward.
🔗labcentral.org/events-and-me…
Our CEO @aedwards02 joined @jonchee_excedr on @Excedr’s Biotech Startups Podcast 🎙️
In Part 1 of 4, he shares how early wonder, queerness, & a few real-life “Ms. Frizzles” helped shape his path—and KiraGen’s mission to conquer the TME.
🚀 Big news! KiraGen Bio is a Boston Regional Finalist in the @HarvardHBS New Venture Competition – Alumni Track!
This is a huge milestone for our AI-driven CAR-T therapies tackling solid tumors like GBM.
Next stop: Global Finals for a chance at $75K!
Onwards and Upwards! 🏆
What if you could address the fundamental barriers to cell therapy effectiveness in solid tumors, rather than merely mitigating secondary functional impairments?
What if you could target the root cause of cell therapy's limited success in solid tumors—the diverse immunosuppressive mechanisms within the tumor microenvironment (TME)?